Suppr超能文献

使用膀胱肿瘤相关分析物检测来确定膀胱癌患者随访中膀胱镜检查的类型。英国和爱尔兰膀胱肿瘤抗原研究组。

The use of the bladder-tumour associated analyte test to determine the type of cystoscopy in the follow-up of patients with bladder cancer. The United Kingdom and Eire Bladder Tumour Antigen Study Group.

出版信息

Br J Urol. 1997 Mar;79(3):362-6.

PMID:9117214
Abstract

OBJECTIVE

To assess the use of the bladder-tumour associated analyte test (BTA, Bard UK) to determine whether patients with bladder cancer scheduled for cystoscopy under general anaesthesia can have local anaesthesia instead.

PATIENTS AND METHODS

A total of 272 patients who were scheduled for general anaesthesia cystoscopy were entered into a prospective multicentre study. The BTA test was performed on a specimen of freshly voided urine and the type of cystoscopy was determined according to whether the result was positive or negative. Patients with a negative BTA result were examined with the flexible instrument, under local anaesthesia, instead of the planned general anaesthetic cystoscopy.

RESULTS

In 59 patients, the BTA test was positive and tumour was found (true positive), in 145 patients the test was negative and cystoscopy was negative (true negative), in 25 patients the test was positive and cystoscopy was negative (false positive) and in 43 patients, the test was negative but tumour was found on flexible cystoscopy; the patient underwent subsequent cystoscopy under general anaesthesia (false negative). The sensitivity and specificity were 58% and 86% respectively. The use of the BTA test resulted in fewer patients needing cystoscopy under general anaesthesia and saved about 25,500 POUNDS ($31,000) OR 76 POUNDS ($114) PER PATIENT.

CONCLUSION

THE integration of the BTA test into the follow-up of patients with bladder cancer may help to select those suitable for cystoscopy, under a local anaesthetic and this will result in cost savings as well as sparing patients the more invasive procedure. The test is not sufficiently sensitive to replace cystoscopy and there were false-negative results despite high-grade recurrence. Thus, when the test is used as part of a follow-up programme, a timely back-up of cystoscopy under general anaesthesia should be arranged for patients with false-negative results.

摘要

目的

评估膀胱肿瘤相关分析物检测(BTA,英国巴德公司)的应用,以确定计划在全身麻醉下进行膀胱镜检查的膀胱癌患者是否可改为局部麻醉。

患者与方法

共有272例计划接受全身麻醉下膀胱镜检查的患者纳入一项前瞻性多中心研究。对新鲜晨尿标本进行BTA检测,并根据结果阳性或阴性确定膀胱镜检查类型。BTA检测结果为阴性的患者采用软性器械在局部麻醉下进行检查,而非计划中的全身麻醉下膀胱镜检查。

结果

59例患者BTA检测呈阳性且发现肿瘤(真阳性),145例患者检测呈阴性且膀胱镜检查结果为阴性(真阴性),25例患者检测呈阳性但膀胱镜检查结果为阴性(假阳性),43例患者检测呈阴性但软性膀胱镜检查发现肿瘤;这些患者随后接受了全身麻醉下的膀胱镜检查(假阴性)。敏感性和特异性分别为58%和86%。使用BTA检测减少了需要全身麻醉下膀胱镜检查的患者数量,每位患者节省约25,500英镑(31,000美元)或76英镑(114美元)。

结论

将BTA检测纳入膀胱癌患者的随访中,可能有助于选择适合在局部麻醉下进行膀胱镜检查的患者,这将节省成本,并使患者避免接受侵入性更强的检查。该检测的敏感性不足以替代膀胱镜检查,尽管存在高级别复发,但仍有假阴性结果。因此,当该检测作为随访计划的一部分使用时,对于检测结果为假阴性的患者,应及时安排全身麻醉下膀胱镜检查作为后备检查。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验